Bessemer Group
RCUS icon

Bessemer Group’s Arcus Biosciences RCUS Stock Holding History

Bessemer Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9K Hold
429
– – ﹤0.01% 2148
2025
Q4 		$10K Buy
429
+101
+31% +$2.06K ﹤0.01% 2108
2025
Q3 		$4K Buy
328
+294
+865% +$3.06K ﹤0.01% 2202
2025
Q2 		$0 Hold
34
– – ﹤0.01% 2602
2025
Q1 		$0 Buy
+34
New +$394 ﹤0.01% 2683
2024
Q4 		– Sell
-70
Closed -$1K – 2647
2024
Q3 		$1K Buy
+70
New +$1.1K ﹤0.01% 2514
2023
Q4 		– Sell
-124
Closed -$2K – 2260
2023
Q3 		$2K Buy
124
+61
+97% +$1.23K ﹤0.01% 2017
2023
Q2 		$1K Buy
+63
New +$1.2K ﹤0.01% 2210
2020
Q3 		– Sell
-47,800
Closed -$1.18M – 1608
2020
Q2 		$1.18M Buy
+47,800
New +$1.29M ﹤0.01% 692

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Bessemer Group's RCUS Position: Q1 2026 in Review

Bessemer Group held its Arcus Biosciences (RCUS) position steady in Q1 2026 at 429 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #2148.

Bessemer Group first reported a position in RCUS in Q2 2020 and has held it in 9 quarters since. The position peaked at $1.18M in Q2 2020. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Bessemer Group held 429 shares of Arcus Biosciences worth $9K as of Q1 2026.
  • Bessemer Group left its Arcus Biosciences share count unchanged in Q1 2026.
  • Arcus Biosciences made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #2148 holding.
  • Bessemer Group first reported a position in Arcus Biosciences in Q2 2020 and has held it in 9 quarters since.
  • Bessemer Group's Arcus Biosciences position peaked at $1.18M in Q2 2020.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.